Advertisement

Topics

MULTIMEDIA: U.S. Food And Drug Administration Approves Pfizer’s XELJANZ® (tofacitinib citrate) for Adults with Moderately to Severely Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response or Intolerance to Methotrexate

20:09 EST 7 Nov 2012 |

First RA Treatment Approved in a New Class of Medicines Known as JAK Inhibitors

First New Oral Disease-Modifying Antirheumatic Drug (DMARD) for RA in More Than 10 Years

NEW YORK--(BUSINESS WIRE)--This release has been updated with multimedia.

Language: 
English
Contact HTML: 

Pfizer Inc.
Media:
Victoria Davis, 484-865-5194
Victoria.Davis@pfizer.com
or
Investors:
Jennifer Davis, 212-733-0717
Jennifer.M.Davis@pfizer.com






Ticker Slug: 
Ticker:
PFE
Exchange:
NYSE
ISIN:
US7170811035

read more

Original Article: MULTIMEDIA: U.S. Food And Drug Administration Approves Pfizer’s XELJANZ® (tofacitinib citrate) for Adults with Moderately to Severely Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response or Intolerance to Methotrexate

NEXT ARTICLE

More From BioPortfolio on "MULTIMEDIA: U.S. Food And Drug Administration Approves Pfizer’s XELJANZ® (tofacitinib citrate) for Adults with Moderately to Severely Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response or Intolerance to Methotrexate"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...